Literature DB >> 12843003

Coagulation activation and long-term outcome in acute coronary syndromes.

Diego Ardissino1, Piera Angelica Merlini, Kenneth A Bauer, Marcello Galvani, Filippo Ottani, Franca Franchi, Federico Bertocchi, Robert D Rosenberg, Pier Mannuccio Mannucci.   

Abstract

After an episode of unstable angina or myocardial infarction, a high proportion of patients show biochemical signs of coagulation activation, expressed as persistently elevated thrombin generation, in their blood. It is not known whether this has any influence on long-term outcome. In this prospective multicenter cohort study, we assessed the relation of persistently elevated thrombin generation to outcome in 319 consecutive patients with acute coronary syndromes enrolled in the Global Use of Strategies To Open occluded coronary arteries (GUSTO) IIb trial. Plasma prothrombin fragment 1 + 2 levels, an index of "in vivo" thrombin generation, was measured during the acute phase and after 1, 6, and 12 months, and its relation to outcome was assessed during a median 29-month follow-up period. The primary end point of cardiac death or myocardial (re)infarction occurred in 61 patients (19%). There was a U-shaped relationship between plasma prothrombin fragment 1 + 2 levels and the risk of developing the primary end point; intermediate levels (1.5-1.9 nM) were associated with the lowest risk, whereas both higher (> 1.9 nM) and lower (< 1.5 nM) values were associated with an increased risk (relative risk [RR] 1.56 and 95% confidence interval [CI], 1.25-2.28; RR, 1.35 and 95% CI, 1.11-1.86, respectively). After an episode of acute coronary syndrome, both high and low levels of thrombin generation are predictors of an increased risk of an unfavorable outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843003     DOI: 10.1182/blood-2002-03-0954

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  The role of oral anticoagulant therapy in patients with acute coronary syndrome.

Authors:  Jae Youn Moon; Deepa Nagaraju; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Ther Adv Hematol       Date:  2017-10-13

Review 2.  Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?

Authors:  Paul Guedeney; Birgit Vogel; Roxana Mehran
Journal:  Interv Cardiol       Date:  2018-05

3.  Changes in haemostatic and platelet activation markers in non-dipper hypertensive patients.

Authors:  Athanasia Agorasti; Efthimia Mourvati; Theodoros Trivellas; Vasilios Papadopoulos; Ioanna Bazntiara; Anna Christoforidou; Ploumis Passadakis
Journal:  Int Urol Nephrol       Date:  2011-03-09       Impact factor: 2.370

Review 4.  Global coagulation assays in hypercoagulable states.

Authors:  Hui Yin Lim; Geoffrey Donnan; Harshal Nandurkar; Prahlad Ho
Journal:  J Thromb Thrombolysis       Date:  2022-01-08       Impact factor: 2.300

5.  ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.

Authors:  Amine Boussofara; Lobna Laroussi; Hela Baccouche; Emna Bennour; Sami Kasbaoui; Hbib Triki; Ibn El Haj Zied; Ikram Kammoun; Afef Ben Halima; Faouzi Addad; Sonia Marrakchi; Neila Ben Romdhane; Salem Kachboura
Journal:  Eur J Clin Pharmacol       Date:  2020-08-06       Impact factor: 2.953

Review 6.  Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review.

Authors:  Peter Khalil; Ghazal Kabbach
Journal:  Curr Cardiol Rep       Date:  2019-01-28       Impact factor: 2.931

7.  Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.

Authors:  Oliver Borst; Patrick Münzer; Nada Alnaggar; Sascha Geue; Roland Tegtmeyer; Dominik Rath; Michal Droppa; Peter Seizer; Stefan Heitmeier; Johan W M Heemskerk; Lisa K Jennings; Robert F Storey; Dominick J Angiolillo; Bianca Rocca; Henri Spronk; Hugo Ten Cate; Meinrad Gawaz; Tobias Geisler
Journal:  Blood Adv       Date:  2018-03-27

8.  Alterations in prothrombin time and activated partial thromboplastin time in patients with acute myocardial infarction.

Authors:  Haseeb A Khan; Abdullah S Alhomida; Tamader Y Al Rammah; Samia H Sobki; Mohammad S Ola; Adnan A Khan
Journal:  Int J Clin Exp Med       Date:  2013-04-12

9.  CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.

Authors:  D A Sychev; O A Baturina; K B Mirzaev; E Rytkin; D V Ivashchenko; D A Andreev; K A Ryzhikova; E A Grishina; P O Bochkov; R V Shevchenko
Journal:  Pharmgenomics Pers Med       Date:  2020-01-23

10.  Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19.

Authors:  Marco G Mennuni; Roberta Rolla; Leonardo Grisafi; Enrico G Spinoni; Andrea Rognoni; Veronica Lio; Luigi M Castello; Pier P Sainaghi; Mario Pirisi; Gian Carlo Avanzi; Marco Krengli; Mattia Bellan; Daniela Ferrante; Gianluca Aimaretti; Umberto Dianzani; Giuseppe Patti
Journal:  J Thromb Thrombolysis       Date:  2021-06-10       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.